Design and Structural Optimization of Dual FXR/PPARδ Activators.

Area of Science:

• Pharmacology
• Hepatology
• Molecular Biology

Background:

• Nonalcoholic steatohepatitis (NASH) is a severe liver condition linked to metabolic syndrome with increasing global incidence.
• Farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) delta are validated molecular targets for NASH therapy.
• A combined approach targeting both FXR and PPARδ may offer enhanced therapeutic efficacy for NASH.

Purpose of the Study:

• To design and develop a minimal dual activator scaffold targeting both FXR and PPARδ.
• To create a potent and balanced dual FXR/PPARδ modulator with high selectivity.
• To validate the activation of FXR and PPARδ in cellular models.

Main Methods:

• Rational design and computer-aided refinement of a dual FXR/PPARδ activator scaffold.
• Pharmacophore fusion from selective agonists of FXR and PPARδ.
• In vitro cellular assays to assess receptor activation and selectivity.

Main Results:

• A novel dual FXR/PPARδ activator scaffold was successfully designed.
• The lead compound was structurally refined into a potent and balanced dual activator.
• The resulting modulator demonstrated high selectivity over related nuclear receptors.
• The dual activator effectively activated FXR and PPARδ in native cellular settings.

Conclusions:

• A potent and selective dual FXR/PPARδ modulator has been developed.
• This dual activator represents a promising multitarget therapeutic strategy for NASH.
• Further investigation into the clinical efficacy of this approach is warranted.